American Green Inc (ERBB): That's nice. So are you saying your rema...

That's nice. So are you saying your remark

neilbolton · 2005-12-08T14:56:00.2330000Z

That's nice. So are you saying your remark about the financing and S4 was based on a complete misunderstanding of some post I made, since I have only ever asked others to substantiate their claims in respect to this matter and have never made any claims myself in regards to it?

Play Episode

4min

Proactive - Interviews for investors

Ananda Develops U.S. presence as lead drug advances to Phase 1 clinical study

Ananda Pharma CEO Melissa Sturgess joined Steve Darling from Proactive to announce the company’s shares have begun trading on the OTCQB market in the United States, a strategic move that expands Ananda’s visibility and access to U.S. investors. The UK-based biopharmaceutical company is focused on developing regulatory-approved cannabinoid medicines for complex and chronic medical conditions. Sturgess emphasized the significance of entering the U.S. market, not only from a capital markets perspective but also as a key future territory for Ananda’s clinical and commercial ambitions. She also highlighted recent progress in the company’s clinical development pipeline, particularly around its lead investigational drug candidate, MRX1. Ananda recently received approval from the Alfred Hospital Human Research Ethics Committee in Australia to initiate a Phase 1 pharmacokinetic study of MRX1. The study will evaluate the safety, tolerability, and pharmacokinetics of two dose levels of the CBD-based drug in a cohort of 20 healthy adult volunteers—10 biological males and 10 biological females—to address known sex differences in CBD metabolism. MRX1 is a high-purity, pharmaceutical-grade cannabidiol (CBD) formulation developed under rigorous quality standards to ensure consistency, safety, and clinical reliability. It is intended for the treatment of chronic inflammatory pain conditions, where current treatment options often fall short in efficacy or come with undesirable side effects. Sturgess noted that this ethics approval marks a critical milestone in the company’s journey toward regulatory approval and commercial readiness. The trial is expected to generate key safety and dosing data to support future Phase 2 studies targeting patients with unmet needs in chronic pain management. #proactiveinvestors #aqse #ana #cbd #otcqb #MRX1 #CBDDrugDevelopment #CannabinoidTherapy #ClinicalTrials #FDAApproval #PharmaNews #BiotechStocks #OTCQB #GWPharma #CBDMedicine #ChronicPainTreat

Proactive - Interviews for investors

ZRCN expands global reach as it reinvents stud finder tech for the next generation

ZRCN CEO John Stauss joined Steve Darling from Proactive to discuss the company’s transformation from a family-founded private firm to a publicly traded innovator with global ambitions. ZRCN Inc., the parent of Zircon Corporation, is best known for its electronic stud finders—a product category it has long dominated and now plans to revolutionize once again. Stauss explained how the company has used Silicon Valley R&D to modernize a traditionally stagnant tool sector, solving everyday frustrations like locating wall studs without damaging drywall surfaces. “We solved that problem,” he said, pointing to the company’s long-standing reputation for reliability in wood-frame construction markets. Beyond its classic offerings, ZRCN has broadened its product line to include devices that detect rebar, metal piping, and live AC wiring—addressing growing needs in both residential and commercial settings. These innovations are helping the company gain traction in international markets, expanding beyond North America where it first established its foothold. Looking ahead to 2025, Stauss revealed the company is gearing up to launch a new breakthrough technology that could reinvent the very category it pioneered. “Yes, yes, yes to all of the above,” he said when asked if the company was refining, innovating, and expanding at the same time. This next phase of growth will be driven by a mix of enhanced features, an expanded product portfolio, and wider global penetration. The CEO also reflected on how pandemic-era home improvement booms bolstered demand, and how ZRCN’s resilient supply chain enabled the company to deliver when competitors couldn’t. Now, with the company entering the public markets, investor engagement and transparency are becoming top priorities. #proactiveinvestors #otcqx #zrcn #StudFinder #HomeImprovement #ConstructionTech #DIYTools #InvestorUpdate #SiliconValleyTech #ElectronicSensors #GlobalExpansion #HomeRenovation #SupplyChain

Proactive - Interviews for investors

Ilika CEO Graeme Purdy on new scale-up milestone for Goliath battery

Ilika PLC CEO Graeme Purdy talked with Proactive's Stephen Gunnion about the company’s latest progress in scaling up its Goliath solid-state battery technology. The discussion focused on improved results from Ilika’s collaboration with the UK Battery Industrialisation Centre (UKBIC). Purdy said: “We’re seeing an improved yield out of the industrialised process,” adding that this reduces waste and lowers costs. More notably, the batteries produced via UKBIC’s process outperform those created on Ilika’s pilot line, showing stronger power density and faster charge-discharge capabilities. Purdy confirmed the project’s shift from process to performance, marking the completion of a £2.7 million grant-supported programme funded by the Advanced Propulsion Centre. He also referenced recent government pledges of £2 billion to back automotive electrification, suggesting that future grant funding could help support Ilika’s product roadmap without shareholder dilution. Looking ahead, Ilika plans to release its P1.5 prototypes—10Ah cells—later this summer. Once enough testing data is gathered, the batteries will be shared with OEMs and Tier 1 suppliers enrolled in its evaluation programme. Purdy also teased the release of 50Ah P2 prototypes by year-end, built on insights gained from the Faraday Battery Challenge. Visit Proactive’s YouTube channel for more videos, and don’t forget to give the video a like, subscribe to the channel and enable notifications for future content. #IlikaPLC #GoliathBattery #SolidStateBatteries #EVTechnology #BatteryInnovation #UKBIC #AutomotiveElectrification #AdvancedPropulsion #BatteryManufacturing #GraemePurdy

Proactive - Interviews for investors

Optima Health CEO on Congate acquisition and growth strategy

Optima Health PLC chief executive Jonathan Thomas talked with Proactive's Stephen Gunnion about the company's acquisition of Ireland-based Cognate Health. This deal marks Optima Health’s first foray outside the UK and is aligned with its strategy to supplement organic growth through mergers and acquisitions. Thomas said the move adds around €7 million in revenue and approximately £1 million in EBITDA to the group. Cognate Health is described as a strong platform with 30 clinic facilities across Ireland and around 60 experienced personnel, along with a network of clinicians. According to Thomas, “It’s a really great platform… in addition to obviously the financial aspects… really great opportunities to collaborate, revenue synergies and grow the businesses collectively.” He explained that expanding into a new regulated market provides access to multinational clients seeking services across both the UK and Ireland. The acquisition allows Optima Health to tailor services across jurisdictions while opening up new cross-sell opportunities. Thomas added that the company expects to announce more acquisitions during the year, with several discussions currently underway. Visit Proactive’s YouTube channel for more in-depth business updates and interviews. Don’t forget to give the video a like, subscribe to the channel, and enable notifications so you never miss a story. #OptimaHealth #CognateHealth #HealthcareAcquisition #MergersAndAcquisitions #JonathanThomas #OccupationalHealth #WorkplaceWellbeing #IrelandHealthcare #BusinessExpansion #ProactiveInvestors

Followers	3
Posts	567
Boards Moderated	0
Alias Born	01/14/2005

Volume:	5,733,385
Day Range:	0.0003 - 0.0005
Bid:	0.0003
Ask:	0.0004
Last Trade Time:	3:50:53 PM EDT
Total Trades:	27

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

ERBB Detailed Quote

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Go Ad-Free